-
EP4209220
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4209220
| EP4209220 - COMPOSITION FOR AMELIORATING, PREVENTING, OR TREATING MUSCULAR ATROPHY OR SARCOPENIA, CONTAINING 2'-FL [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 01.08.2025 Database last updated on 19.03.2026 | |
| Former | Request for examination was made Status updated on 09.06.2023 | ||
| Former | The international publication has been made Status updated on 02.06.2023 | ||
| Former | unknown Status updated on 24.02.2023 | Most recent event Tooltip | 19.12.2025 | New entry: Renewal fee paid | Applicant(s) | For all designated states Advanced Protein Technologies Corp. 7F, 147, Gwanggyo-ro Yeongtong-gu Suwon-si, Gyeonggi-do 16229 / KR | [2023/28] | Inventor(s) | 01 /
KIM, Yeon Ji Daegu 41062 / KR | 02 /
KIM, Kyung Ho Daegu 41062 / KR | 03 /
SHIN, Chul Soo Suwon-si, Gyeonggi-do 16563 / KR | 04 /
YOON, Jong Won Seongnam-si, Gyeonggi-do 13525 / KR | 05 /
JEON, Seon Min Daegu 42270 / KR | 06 /
SONG, Young Ha Yongin-si, Gyeonggi-do 16961 / KR | 07 /
YOO, Jong Gil Suwon-si, Gyeonggi-do 16316 / KR | 08 /
KIM, Ji Eun Hwaseong-si, Gyeonggi-do 18319 / KR | [2023/28] | Representative(s) | RGTH Patentanwälte PartGmbB Neuer Wall 10 20354 Hamburg / DE | [2023/28] | Application number, filing date | 21953623.2 | 13.12.2021 | [2023/28] | WO2021KR18900 | Priority number, date | KR20210162483 | 23.11.2021 Original published format: KR 20210162483 | [2023/28] | Filing language | KO | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2023096005 | Date: | 01.06.2023 | Language: | KO | [2023/22] | Type: | A1 Application with search report | No.: | EP4209220 | Date: | 12.07.2023 | Language: | EN | [2023/28] | Search report(s) | International search report - published on: | KR | 01.06.2023 | (Supplementary) European search report - dispatched on: | EP | 29.07.2024 | Classification | IPC: | A61K31/702, A61P21/00, A61P21/06, A23L33/125 | [2024/35] | CPC: |
A61P21/06 (EP,US);
A61K31/702 (EP,US);
A23L33/10 (EP);
A23L33/125 (EP);
A23L33/21 (EP);
A23L33/40 (EP);
|
| Former IPC [2023/28] | A61K31/702, A61P21/00, A23L33/125 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/28] | Title | German: | ZUSAMMENSETZUNG ZUR LINDERUNG, PRÄVENTION ODER BEHANDLUNG VON MUSKELATROPHIE ODER SARKOPENIE MIT 2'-FL | [2023/28] | English: | COMPOSITION FOR AMELIORATING, PREVENTING, OR TREATING MUSCULAR ATROPHY OR SARCOPENIA, CONTAINING 2'-FL | [2023/28] | French: | COMPOSITION DESTINÉE À AMÉLIORER, À PRÉVENIR OU À TRAITER L'ATROPHIE MUSCULAIRE OU LA SARCOPÉNIE, CONTENANT DU 2'-FL | [2023/28] | Entry into regional phase | 24.02.2023 | Translation filed | 24.02.2023 | National basic fee paid | 24.02.2023 | Search fee paid | 24.02.2023 | Designation fee(s) paid | 24.02.2023 | Examination fee paid | Examination procedure | 24.02.2023 | Examination requested [2023/28] | 14.02.2025 | Amendment by applicant (claims and/or description) | 14.02.2025 | Date on which the examining division has become responsible | 01.08.2025 | Despatch of a communication from the examining division (Time limit: M04) | 19.11.2025 | Reply to a communication from the examining division | Fees paid | Renewal fee | 29.12.2023 | Renewal fee patent year 03 | 31.12.2024 | Renewal fee patent year 04 | 18.12.2025 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [X] WO2016029113 (ABBOTT LAB et al.) [X] 1-11 * page 4, lines 19-22 * * page 8, lines 9-22 * * page 14, lines 15-20 * * page 27, line 16 - page 28, line 24 * * page 30, lines 5-10 * * claims 1, 9, 25, 27, 30, 36-37 * | [X] WO2021011905 (UNIV CALIFORNIA et al.) [X] 1-11 * page 3, paragraphs [0010]-[0013] * * page 8, paragraph [0038] * * pages 11-12, paragraph [0047] * * claims 1, 8, 14, 15, 17 * * page 13, paragraph [0051] * | [X] WO2020174386 (NUTRIBAM BVBA et al.) [X] 11 * page 17; example 4 * * claims 15, 16, 26, 29 * | [E] WO2022115347 (INTRINSIC MEDICINE INC et al.) [E] 1-11 * page 1, lines 19-22 * * page 12, line 27 - page 13, line 4 * * page 13, line 22 - page 14, line 21 * * page 15, line 14 - page 16, line 15 * * page 16, lines 31-33 * * page 33; examples 1, 2 * * claims 1, 5, 25, 27-31, 34-35, 47, 61 * | International search | [A] KR20180102431 (COSMAX INC et al.) [A] 1-11 * See claims 1-13. * | [A] KR20210116783 (UNIV AJOU IND ACADEMIC COOP FOUND et al.) [A] 1-11 * See entire document. * | [A] KR20210013007 (DUPONT NUTRITION BIOSCI APS et al.) [A] 1-11 * See entire document. * | [A] KR20190045079 (AP TECH CORP et al.) [A] 1-11 * See entire document. * | [A] KR20190130720 (AP TECH CORP et al.) [A] 1-11 * See entire document. * | Examination | SHANNON REAGAN-SHAW ET AL: "Dose translation from animal to human studies revisited", THE FASEB JOURNAL, vol. 22, no. 3, 1 March 2008 (2008-03-01), US, pages 659 - 661, XP055542714, ISSN: 0892-6638, DOI: 10.1096/fj.07-9574LSF DOI: http://dx.doi.org/10.1096/fj.07-9574LSF |